特发性膜性肾病免疫抑制治疗的最新进展  

Advanced progress in immunosuppressive therapy for idiopathic membranous nephropathy

作　　者：范耀冰 李艳艳(综述)[1] 吴红赤(审校)[1] FAN Yaobing;LI Yanyan;WU Hongchi(Department of Nephrology,First Affiliated Hospital of Harbin Medical University,Harbin 150001,China)

机构地区：[1]哈尔滨医科大学附属第一医院肾内科,哈尔滨150001

出　　处：《临床与病理杂志》2021年第7期1703-1708,共6页Journal of Clinical and Pathological Research

基　　金：黑龙江省教育厅科学技术研究项目(12541264)。

摘　　要：特发性膜性肾病(idiopathic membranous nephropathy,IMN)是肾病综合征最常见的病因之一,发病率逐年增加,30%~40%的IMN患者有持续性尿蛋白,并逐渐进展为终末期肾病,严重影响人们的健康。近几年各类新型免疫抑制剂投入临床使用,如新型单克隆抗体、蛋白酶体抑制剂、补体抑制剂,为IMN治疗提供了新的治疗方案。Idiopathic membranous nephropathy(IMN)is one of the most common causes of nephrotic syndrome,and its incidence rate is increasing year by year.There are 30%–40%of IMN patients with persistent urinary protein which can develop to an end-stage renal disease,so it seriously affects people’s health.In recent years,various new immunosuppressive agents have been introduced into clinic,such as new monoclonal antibodies,proteasome inhibitors,complement inhibitor,has provided a new treatment regimen for IMN.

关 键 词：特发性膜性肾病 免疫抑制治疗 新型单克隆抗体 蛋白酶体抑制剂 补体抑制剂 

分 类 号：R692[医药卫生—泌尿科学]